Changchun High-Tech Industry (Group) (000661) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was ¥2.59 billion, down 13.69% year-over-year; net profit attributable to shareholders was ¥276 million, down 41.67% year-over-year.

• Major subsidiaries saw mixed results: Jinsai Pharma revenue fell 18.24%, Baike Biotech revenue fell 9.21%, Huakang Pharma revenue rose 4.69%, and Gaoxin Real Estate revenue surged 234.33%.

Financial highlights

• Operating cash flow increased 92.27% year-over-year to ¥1.10 billion.

• Basic and diluted EPS were ¥0.69, down 41.03% year-over-year.

• Total assets at quarter-end were ¥30.77 billion, up 2.28% from year-end 2025.

• Shareholders’ equity attributable to listed company shareholders rose 1.24% to ¥22.28 billion.

Segment performance

• Jinsai Pharma: Revenue ¥2.14 billion, net profit ¥334 million, both down significantly year-over-year.

• Baike Biotech: Revenue ¥147 million, net loss ¥3 million, net profit down 426.43% year-over-year.

• Huakang Pharma: Revenue ¥186 million, net profit ¥14 million, both up year-over-year.

• Gaoxin Real Estate: Revenue ¥103 million, net profit ¥1.34 million, both up sharply year-over-year.